Teprenone [mixture of (5E,9E,13E)- and (5Z,9E,13E)- isomers] , ≥95.0% , 6809-52-5
Synonym(s):
6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraen-2-one, mixture of (5E,9E,13E) and (5Z,9E,13E) isomers;GGA;Selbex;Teprenone;UNII-S8S8451A4O
CAS NO.:6809-52-5
Empirical Formula: C23H38O
Molecular Weight: 330.55
MDL number: MFCD00866901
EINECS: 614-276-0
Pack Size | Price | Stock | Quantity |
200MG | RMB135.20 | In Stock |
|
1G | RMB440.80 | In Stock |
|
5G | RMB1768.00 | In Stock |
|
others | Enquire |
PRODUCT Properties
Boiling point: | bp0.01 155-160° |
Density | d420.5 0.9081 |
refractive index | nD20 1.4947 |
storage temp. | -20°C |
solubility | DMSO: >5mg/mL |
form | liquid |
color | clear |
Merck | 14,9228 |
Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. |
InChIKey | SBOCYPUKNYDTSX-DMLVRTFPSA-N |
LogP | 8.200 (est) |
Description and Uses
Teprenone (geranylgeranylacetone) is an antiulcer agent whose synthesis was inspired by the gastric protecting properties of Coenzyme Q10. Teprenone is reported to act via enhancement of gastric mucosal glycoprotein secretion.
An anti-ulcerative. Geranylgeranylacetone can induce expression of HSP70, HSPB8, and HSPB1. Induction of HSP70 expression is protective against the development of various diseases, such as inflammatory bowel disease, hypoxic/ischemic brain injury and spinal and bulbar muscular atrophy (cytoprotective and anti-inflammatory effects). Reports indicate that GGA protects against NSAID-induced gastric and intestinal lesions by induction of HSP70 expression. Other studies have shown that GGA induces expression of HSPB8 and HSPB1 and reduces the formation of amyloid oligomers as well as insoluble aggregates in HSPB5 R120G TG mice.
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H315-H319-H335 |
Precautionary statements | P261-P305+P351+P338 |
WGK Germany | 3 |
RTECS | RA5391300 |
HS Code | 2914.19.0000 |